Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 23, 2025. 

NeurologyLive® Friday 5 — May 23, 2025

Videos

Neurologists Ari Green, MD, and Paul Tesar, PhD, discuss the current limitations of remyelination assessment tools in MS and highlight efforts to develop more reliable clinical measures.

From Imaging to Biomarkers: Improving Remyelination Assessment in MS

A recent study suggests rituximab may benefit CIDP patients, showing improvement in neurofilament levels and clinical outcomes after treatment.

Rituximab’s Effect on NfL Levels Points to Possible Therapeutic Advantage in CIDP

The assistant professor of neurology at Robert Wood Johnson Medical School talked about a collaborative initiative that aims to address AD disparities in Asian and Pacific Islander American populations. [WATCH TIME: 3 minutes]

Enhancing Alzheimer Care in Asian and Pacific Islander Communities Through RCASIA: Brad Kamitaki, MD

, has been with the team since September 2022. Follow her on Twitter 

In this initial episode, experts Ari Green, MD, and Paul Tesar, PhD, break down the biological foundation and therapeutic importance of remyelination in multiple sclerosis.

Defining Remyelination in the Context of Multiple Sclerosis

AHN's neuro-oncology program aims to revolutionize brain and spine tumor care with innovative therapies, personalized treatment plans, and advanced research initiatives.

Rewiring Brain and Spine Tumor Care: AHN’s Coordinated, Personalized Approach   

The multiple sclerosis condition center is a resource for clinical news on the diagnosis, treatment, and management of multiple sclerosis. | NeurologyLive.


Multiple Sclerosis | Clinical Neurology News | NeurologyLive

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

PNS 2025

AAN 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1.125rem

Clinical

 MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

In this episode, "Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis," Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the new McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 

40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

. Ontaneda, who also serves as an assistant professor of neurology, discussed the most notable changes to the criteria and how it may help towards improving rates of misdiagnosis and missed diagnosis. He spoke on the incorporation of new biomarkers, such as central vein sign and paramagnetic rim lesions, and the ability to diagnose MS in stages before clinical presentation shows. Furthermore, Ontaneda gave some perspective on the areas of the new criteria that will take some time to adjust to, as well as how these criteria may change the philosophical perspective of the disease as a whole.


The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Potential Regulatory Submission for Inebilizumab in Myasthenia Gravis Following Positive Phase 3 MINT Data

Parkinson Agent Tavapadon Meets Primary and Secondary End Points as Monotherapy in Phase 3 TEMPO-1 Trial

Sage Therapeutics and Biogen Officially Announce Ending of SAGE-324 Program in Essential Tremor

 – Focus and direction of new diagnostic criteria

 – Overviewing specific changes to McDonald criteria

 – Approach to diagnosing pre-MS; treating radiologically isolated syndrome earlier

 – Incorporation of new biomarkers, central vein sign, paramagnetic rim lesions, OCT

 – Unanswered questions/challenges left out of the diagnostic criteria

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

European Committee for Treatment and Research in Multiple Sclerosis Congress (ECTRIMS)

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 27 minutes]

Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

Episode 47, "Incorporating Physical Therapy Into MS Care," features an exclusive interview with Patricia Bobryk, MHS, PT, MSCS, ATP, physical therapist, UC Health, and cochair, 

International Organization of MS Rehabilitation Therapists (IOMSRT)

. Bobryk shared her insight into the clinical care of MS from the perspective of a rehabilitative specialist, and the importance of including physical therapy approaches as part of the multidisciplinary approach to care as early as possible to ensure more beneficial long-term outcomes for patients, also speaking to the latest advances and developments in rehabilitative medicine.

The stories feature in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Noncontact Boxing Exercise Assessed for Parkinson Disease Benefit

Opicapone Demonstrates Small Benefit for Sleep in Parkinson Disease

Amylyx Announces Plans to Submit NDA for AMX0035 for ALS

Episode Breakdown

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Patricia Bobryk, MHS, PT, MSCS, ATP.

Episode 47: Incorporating Physical Therapy Into MS Care

Episode 38, "Advancing MS Care and Awareness," features an interview with Barry Hendin, MD, clinical professor, University of Arizona; director, Multiple Sclerosis Clinic, Banner University Medical Center; and chief medical officer, Multiple Sclerosis Association of America. He shared his perspective on the recent World MS Day on May 30, the impact awareness efforts have had on care, and how treatment has evolved during his time as a multiple scleorsis (MS) physician.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Barry Hendin, MD.

Episode 38: Advancing MS Care and Awareness

A recent large cohort analysis of global MS registry data reported that the incidence and persistence of progression independent of relapse activity varied widely depending on how it was defined.

Observed Differences in PIRA Definition Call for More Standardized Agreement on Term 

Evan L. Smith, PhD, assistant professor of Physical Medicine & Rehabilitation at University of Michigan, discussed how emotional wellbeing, motivation, and evidence-based therapies can significantly influence outcomes in MS.

Psychological Perspective on the Role of Mental Health in MS Rehabilitation and Care

The award ceremony is supported by Viatris and will take place on Thursday, May 29, 2025, at the Phoenix Convention Center in Phoenix, Arizona, during the 2025 CMSC Annual Meeting.

NeurologyLive® and CMSC Announce the Fourth Class of Giants of Multiple Sclerosis® Inductees

Jack P. Antel, MD, professor of neurology and neurosurgery at McGill University, reflected on key advances in neuroimmune research and their implications for understanding and treating MS. 

Evolving Clinical Insights Into Neuroimmune Mechanisms and Multiple Sclerosis Progression

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements. 

Advancing MS Research Through Recognition and Innovation: The John Dystel Prize

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. 

Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD

"What often sets some of the prize winners apart is that these discoveries have led to something translational, something that has ultimately resulted in the development of disease-modifying or other therapies that benefit people living with MS.”

Recognition of research in multiple sclerosis (MS) provides an opportunity to highlight the efforts of investigators who contribute to advancing clinicians’ understanding of the disease. Recent studies have expanded knowledge of MS pathogenesis, including evidence that suggests a potential link between Epstein-Barr virus infection and later MS development. These investigations offer important insight into possible risk factors and help shape future lines of inquiry.

In addition to uncovering disease mechanisms, recognized researchers have also contributed to advancements in diagnostic and imaging technologies. For instance, NIH investigators recently used a 4-dimensional brain map in a nonhuman primate model to identify early MRI changes associated with lesion development, work that may inform future detection strategies.

Similarly, research using single-cell RNA sequencing has revealed more detailed cellular profiles in chronic MS lesions, further contributing to a growing body of knowledge that supports improved MS care.

2025 American Academy of Neurology (AAN) Annual Meeting

, held April 5–9 in San Diego, California, the impact of such contributions was underscored when MS expert 

, was honored with the John Dystel Prize for Multiple Sclerosis Research.

, executive vice president of research at the 

 about the significance of the award, clarifying that although it is a prestigious honor, it is not strictly a lifetime achievement prize. Rather, he noted, that recipients are recognized based on a range of complementary strengths demonstrated across their body of work.

Click here for more coverage of AAN 2025.

REFERENCES
1. Lin JP, Brake A, Donadieu M, et al. 4D marmoset brain map reveals MRI and molecular signatures for onset of multiple sclerosis-like lesions. Science. 2025;387(6737):eadp6325. doi:10.1126/science.adp6325
2. Absinta M, Maric D, Gharagozloo M, et al. A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis. Nature. 2021;597(7878):709-714. doi:10.1038/s41586-021-03892-7
3. Dr. Amit Bar-Or, Penn Medicine Neuroimmunologist, Awarded the 2025 John Dystel Prize for Multiple Sclerosis Research. News Release. National Multiple Sclerosis Society. Published March 20, 2025. Accessed April 8, 2025. https://www.nationalmssociety.org/news-and-magazine/news/bar-or-wins-2025-dystel-prize
4. Bar-Or A. 2025 John Dystel Prize for Multiple Sclerosis Research. Presented at: 2025 AAN Annual Meeting; April 5-9; San Diego, CA. Multiple Sclerosis: Biomarkers in MS.

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

SAP Partners

The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. 

Advancing MS Care Through Early Intervention and Deeper CNS Insights: Jack P. Antel, MD

“If we compare ourselves to the generation before us, they didn't have the tools that we have. In particular, the imaging tools like MRI which allowed us to see the disease, and also the technology for making therapy, especially recombinant molecules.”

Prior research into neuroimmune interactions has helped shape current and future approaches to multiple sclerosis (MS) care. Advances such as in understanding immune-central nervous system (CNS) dynamics have informed the development of targeted therapies, such as B cell–depleting agents, and improved monitoring tools like neurofilament light chain as a biomarker in MS.

Evolving imaging technologies, including PET and MRI, continue to enhance early diagnosis and disease tracking.

These developments reflect how prior insights are contributing to more refined and personalized treatment strategies.

This was a topic featured in the Kenneth P. Johnson Memorial Lecture, presented at the 

2025 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

, held February 27 to March 1, in West Palm Beach, Florida, by 

 professor of neurology and neurosurgery at McGill University.

, ACTRIMS Forum Chair, set the stage with a welcome address. After the Forum, Antel had a conversation with 

 to futher reflect on how advances in imaging and molecular therapies have transformed the field for the MS community. 

During the conversation, he emphasized a paradigm shift toward early therapeutic intervention to prevent relapse-driven disability in patients living with MS. Antel also outlined the emerging realization that systemic immune activity alone may not account for disease progression and that future therapies should address CNS-specific mechanisms. He also highlighted key unanswered questions in neuroimmunology, including the role of Epstein-Barr virus, patient-specific CNS responses, and subtle symptoms like cognitive dysfunction.

Click here for coverage of 2025 ACTRIMS Forum.

REFERENCES
1. Eva L, Pleș H, Covache-Busuioc RA, et al. A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments. Biomedicines. 2023;11(9):2489. Published 2023 Sep 8. doi:10.3390/biomedicines11092489
2. Oh J, Bar-Or A. Precision neuroimmunology in multiple sclerosis - the horizon is near. Nat Rev Neurol. 2024;20(9):507-508. doi:10.1038/s41582-024-00992-6
3. Charabati M, Wheeler MA, Weiner HL, Quintana FJ. Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting. Cell. 2023;186(7):1309-1327. doi:10.1016/j.cell.2023.03.008
4. Antel JP. Neuroimmune Interactions: How Past Lessons Can Inform the Present and Future of MS Care. Presented at ACTRIMS Forum 2025; February 27 to March 1; West Palm Beach, Florida. Kenneth P. Johnson Memorial Lecture.

The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. [WATCH TIME: 4 minutes]

Experts discussed how aging impacts multiple sclerosis management, treatment decisions, and overall patient health.

The Role of Aging in Multiple Sclerosis Care

, held February 27 to March 1, in West Palm Beach, Florida. This CE-accredited meeting featured a single track of scientific and clinical presentations focused on advancing research and treatment for multiple sclerosis (MS) and related disorders. The 2025 theme, "Making Connections," emphasized linking aging to MS pathology, exploring cross-disorder and neuroanatomical connections, bridging data with clinical application, and investigating brain repair and protection. Designed for researchers, clinicians, students, and fellows, the 

 Forum provided opportunities to engage with experts, optimize MS management, and explore emerging concepts in neuroimmunology.

 held a roundtable discussion with MS experts who talked about key advancements in MS treatment and research that were discussed during the 2025 ACTRIMS Forum. The experts shared their thoughts on which sessions from the Forum that could have the most immediate impact on clinical practice and examined how emerging therapies could transform MS treatment in the coming years. They also explored the role of AI and machine learning in MS as well as the increasing focus on aging and MS progression. The panelists in this conversation included neuroimmunologist Moein Amin, MD, neurologist 

In this episode, experts highlighted aging as a key topic in MS care. They emphasized the growing need to understand the biological and clinical implications of aging, including comorbidities, treatment discontinuation, and general health maintenance. As patients with MS live longer because of effective therapies, the experts noted that clinicians are increasingly focusing on personalized approaches that account for aging-related changes and overall wellness.

 So what I'm going to do is ask if anybody has any closing remarks on overall, their time at ACTRIMS, and if they're looking forward to any thing else for the next meeting?

 I would just say one other big topic that was really exciting and we didn't get to talk about necessarily was aging in MS. And that's, again, another kind of relevant topic for all of us clinicians, because many of our patients are continuing to live longer. And with the ability of the disease-modifying treatments to keep the disease more stable over a more prolonged period of time, there's this opportunity to treat patients potentially longer term. We're still trying to understand all the implications of aging in MS—whether that's accelerating biological aging or the effect on immune cells, and what impact that will have on our treatments. That's something that McGinley has been involved in, obviously—whether that’s stopping disease-modifying therapies or potentially de-escalating. So that's an area that I look forward to hearing more about in future meetings as well.

 Yeah, I completely agree. I think we absolutely have an aging population. We think of MS as a young person’s disease, diagnosed in their 20s and 40s. And we're fortunate now that our treatments are quite effective and our patients are living longer, doing better, but it also means that we're caring for patients, well into their sixth, seventh, eighth-plus decades. So understanding the biological changes—both that biological age versus chronological age, the impact of the comorbidities that occur as people age—and then, I mean, some of the work that we presented at ACTRIMS was thinking more about discontinuation.

And Conway gave another wonderful talk on the DISCOMS data and several of the other discontinuation trials, and it's a very hot topic because there's not a clear answer. And so really, as we try to, again, think about a more personalized approach—and that’s some of the work we presented on developing, using machine learning, a personalized risk model for discontinuation—so, efforts in that way. So I think a lot around treatment as our patients are aging, but I think underpinning that is understanding the biology and the other comorbid conditions that are happening. I agree, it's going to be a really important topic as we move forward.

And I guess just building on the aging issue, I think that it really kind of underscores the importance of general health in MS that I've been trying to emphasize more and more with my patients in clinic, as Dr. McGinley was referring to. As patients get older, they get more comorbidities, and there's mounting evidence of the impact of comorbidities on MS. And then, I think it ties together other features as well. There was an interesting abstract about biological age as measured by metabolomic profiles, and how there was a relationship between that and social determinants of health. And we know social determinants of health are also, you know, associated with factors of general health. And so I think it brings together this, you know, the whole picture for patients with MS and how the things that can come with aging also tend to make MS worse. And so that's something that we need to focus on, and we need to encourage our patients to be aware of—to manage their comorbidities, to get appropriate cancer screenings, and to be mindful of their general health. Because I really find that those patients who exercise, who don't smoke, and who take their disease-modifying therapies—they tend to do the best over the long term with their MS.

Experts discussed how aging impacts multiple sclerosis management, treatment decisions, and overall patient health. [WATCH TIME: 5 minutes]

Experts discussed the current and future applications of AI and machine learning in multiple sclerosis research and clinical care, highlighting both opportunities and limitations. 

AI and Machine Learning in MS: Promise and Practicality for Clinical Practice

In this episode, clinicians explored how artificial intelligence and machine learning can be potentially integrated into MS research and practice. They highlighted current uses in imaging, electronic health records, and clinical transcription, as well as future potential in genetic analysis and personalized medicine. Although the promise of these tools is significant, from improving diagnostic accuracy to easing clinical workflows, the clinicians emphasized the importance of understanding their limitations and ensuring close collaboration with data science experts.

: Another hot topic that is being talked about right now in the field, and that was also presented at the meeting, was AI and machine learning—using it in research and also in clinical practice. So, what do you think are maybe the most promising applications from this, and what challenges do you think still remain?

 Yeah, so I think there was a good session led by Russell Takeshi Shinohara, PhD—he was actually leading a machine learning session at the ACTRIMS—that he nicely summarized a lot of the history in using machine learning. He actually noted an interesting fact that I wasn’t aware of either. People proposed using machine learning to analyze MRIs in MS as early as 1989, which was quite surprising to me. There was an early paper he pointed out that used neural networks to identify lesions in MRI for patients with MS back in 1989, which was quite interesting.

But the field obviously is growing—in conjunction with the machine learning field, MS clinicians and researchers are also starting to use more and more of these methods and apply them in various different applications. We also had the Brain Exchange sessions with Dr. Daniel Ontaneda, MD, PhD, which I led and moderated—an interesting discussion between clinicians, researchers, and other involved parties around the use of machine learning in MS research and clinical application.

There’s a lot of different applications. One big application of machine learning is imaging, where we could use machine learning to develop more sensitive and specific imaging contrast—whether that’s reduction of artifacts, developing synthetic sequences that aren’t obtained to reduce scan time, or developing new sequences altogether. Harmonization across different scanners and acquisition techniques, lesion segmentation and phenotyping, identifying diagnostic and prognostic biomarkers such as central vein sign and paramagnetic rim lesions—using automated methods to do those. That’s obviously a hot topic and of interest in neuroimaging.

But there are also a lot of other applications that have come about, including a hot topic, which is ambient listening—that is being used in clinical practice at a lot of centers, where AI can be used to transcribe conversations with the patient. That can save time and also allow the clinician to spend more time with the patient rather than typing into the computer.

There are a lot more applications, including genetic data. There was data presented about using a genetic risk score to potentially diagnose someone with MS using genetic data, which is another area to apply machine learning because of the high dimensionality of the data.

But the main point that came out of our discussion was that although there are a lot of applications, we should look at AI or machine learning as a tool—like any other tool. You can use it to achieve a lot of different things, but the important part is being aware of its limitations and making sure you don’t misapply the tool—similar to MRI, for example. MRI is not perfect. There are limitations, but we use it in clinical practice daily to achieve a lot of different goals. Similarly, AI can be used to achieve a lot of different goals in clinical practice or research. We just have to be aware of the limitations of each technique—which is easier said than done—but that’s something that, in my mind, requires collaboration with data scientists and experts in the field.

 There was a talk by Dan Milea, MD, PhD, from Singapore that I thought was really fascinating, where he was using OCT data and feeding it into a deep learning model. And he was showing that the model could actually identify all sorts of different conditions just from examining patients' retinas—including MS, hypertension, I think Alzheimer disease was also mentioned. So that’s really exciting to me.

Other things, just thinking aspirationally, that I think would be exciting developments for AI and MS would be that we kind of have this wealth of information in our electronic medical records that we try to use for observational studies. But actually getting good data from the electronic medical record is a huge challenge and usually requires manual extraction. We’re getting better at trying to get the data out, but usually you need to understand language in order to grasp what’s going on with each patient. And if we had an AI model that could go through the charts and pull out data—and then analyze it for patterns that maybe we would never think of—I think that could be really exciting.

And then lastly, just on the clinical front, Amin was referring to AI scribes, which we’re supposed to be trying here at Cleveland Clinic soon, and we’re all excited about. But I’m also excited about the prospect of these patients who don’t have a straightforward diagnosis—they come to see you with a suitcase full of records—and the possibility that AI might be able to help us process those records and summarize the findings. Because generally, in clinic, we don’t have enough time, unfortunately, to flip through 1000 pages of records. That’s really exciting to me, and I think it could bring benefit to a lot of patients in the near future.

 I think both of you made excellent points. I think that imaging is definitely the easiest—or the application where we’re already using a lot of AI—and I think that’s the natural starting point. And then I think Conway pointed out a couple of the very clinical applications when it comes to collecting and mining data that really just augment our ability as clinicians to care for patients.

I think another sort of aspirational goal is really the idea of personalized medicine—and Amin kind of alluded to that with the genetics—and there was a lot on proteomics, too. And then Conway’s point about the amount of information in the EHR—we kind of do an algorithm in our head, I think, just based on our medical training, and we try to piece it all together. But the development of more tools that utilize AI to help guide diagnosis and treatment decisions for patients using that individualized approach—I think that would be really fabulous.

Because we've all been reiterating that every MS patient is different when it comes to their biology, their symptoms, their presentation. So there's really not a good one-size-fits-all for any diagnostic or treatment approach. I think the potential of AI and machine learning to help guide that and really augment our ability as clinicians to care for patients would be wonderful.

Experts discussed the current and future applications of AI and machine learning in multiple sclerosis research and clinical care, highlighting both opportunities and limitations. [WATCH TIME: 9 minutes]

Experts discussed the promise and uncertainty surrounding BTK inhibitors and CAR T-cell therapy in addressing progressive multiple sclerosis.

Emerging Therapies and the Future of MS: Insights on BTK Inhibitors and CAR T-Cells

In this episode, experts explored the evolving therapeutic landscape of MS, focusing on Bruton tyrosine kinase (BTK) inhibitors and CAR T-cell therapy. Although BTK inhibitors have shown mixed results in relapsing MS, there is cautious optimism about their potential role in slowing disability progression, particularly as adjunct therapies. The speakers also highlighted the importance of identifying patients with compartmentalized inflammation and emphasized the need for more sensitive imaging and biomarkers in clinical trials. CAR T-cell therapy was discussed as a promising yet early-stage intervention, with an eye on safety and its ability to target previously inaccessible inflammation.

Experts discussed the promise and uncertainty surrounding BTK inhibitors and CAR T-cell therapy in addressing progressive multiple sclerosis. [WATCH TIME: 8 minutes]

Multiple Sclerosis

Latest News